title: Prenatal screening for congenital nephrosis in east Finland: results and impact on the birth prevalence of the disease.
abstract: Congenital nephrosis of the Finnish type (CNF) is inherited as an autosomal recessive trait which maps to the long arm of chromosome 19. The disease causes massive proteinuria, and renal transplantation in early neonatal life is the only effective treatment. Prenatal diagnosis, usually in high-risk families, depends on the analysis of alpha-fetoprotein (AFP) levels in maternal serum (MS) or amniotic fluid (AF). We studied the effectiveness of MSAFP measurement as a method of screening all pregnant women for congenital nephrosis. Between 1 January 1979 and 31 December 1992, all pregnant women (N = 110,858) attending maternity care units in East Finland were offered serum AFP measurement as part of a screening programme. All patients whose MSAFP value was > or = 2.5 multiples of the median (MOM) at 15-18 weeks' gestation were given an ultrasound examination and if no morphological abnormality was found, they were then offered amniocentesis. Altogether, 105,880 pregnant women (96 per cent) in East Finland participated in the screening for CNF. A total of 47 cases of CNF were diagnosed during the study period. Elevated AFP concentrations in maternal serum and amniotic fluid (> or = 2.5 MOM) were found in all screened (44/105,880) affected pregnancies except one. The most typical feature of a CNF pregnancy was a very high AFP concentration in the amniotic fluid. As a result of the screening, the prevalence at birth of CNF decreased from 1:2600 to 1:11,086. The possibility of CNF has to be taken into account in pregnancies with a ¿false-positive' elevated AFP result (normal ultrasound and no detectable acetyl cholinesterase).
authors.affiliation: Department of Obstetrics and Gynecology, University Hospital of Kuopio, Finland.
authors.forename: S
authors.initials: S
authors.lastname: Heinonen
authors.forename: M
authors.initials: M
authors.lastname: Ryynänen
authors.forename: P
authors.initials: P
authors.lastname: Kirkinen
authors.forename: I
authors.initials: I
authors.lastname: Penttilä
authors.forename: K
authors.initials: K
authors.lastname: Syrjänen
authors.forename: M
authors.initials: M
authors.lastname: Seppälä
authors.forename: S
authors.initials: S
authors.lastname: Saarikoski
mesh_terms: D000649:Amniocentesis; D000653:Amniotic Fluid / Q000737:chemistry; D002869:Chromosome Aberrations / Q000175:diagnosis / Q000453:epidemiology; D025063:Chromosome Disorders; D004812:Epidemiologic Methods; D005260:Female; D005387:Finland / Q000453:epidemiology; D005808:Genes, Recessive / Q000235:genetics; D006801:Humans; D007231:Infant, Newborn; D008403:Mass Screening / Q000379:methods*; D009404:Nephrotic Syndrome / Q000151:congenital* / Q000175:diagnosis / Q000453:epidemiology / Q000517:prevention & control; D011237:Predictive Value of Tests; D011247:Pregnancy; D011296:Prenatal Diagnosis / Q000379:methods*; D015995:Prevalence; D000509:alpha-Fetoproteins / Q000032:analysis
chemical_list: D000509:alpha-Fetoproteins